CD19-CAR-T cells (n=8) | Rituximab (n=5) | |
Demographic characteristics | ||
Age, years mean (SD) | 33.2 (9.6) | 56.8 (7.56) |
Sex, female (n) | 7 | 2 |
Type of autoimmune disease (n) | ||
SLE | 6 | 0 |
SSc | 2 | 2 |
GPA | 0 | 3 |
Disease duration, months mean (SD) | 72.7 (64.96) | 44.4 (50.31) |
Autoantibodies to (n) | ||
ANA | 8 | 3 |
dsDNA | 6 | 0 |
Scl-70 | 2 | 1 |
Histone | 4 | 1 |
pANCA | 0 | 1 |
cANCA | 0 | 3 |
Others* | 5 | 1 |
Organ involvement (n) | ||
Mucocutaneous | 8 | 2 |
Pulmonary | 4 | 4 |
Gastrointestinal | 1 | 1 |
Cardiovascular | 2 | 1 |
Renal | 5 | 2 |
MSK | 3 | 0 |
ENT | 0 | 2 |
Haematological† | 6 | 0 |
RTX duration, months mean (SD) | – | 20.2 (29.65) |
Immunosuppressive medication (n) | ||
Glucocorticoid | 0 | 1 |
Other drugs | 0 | 1 |
Categorical variables: numbers, continuous variables: mean, (SD).
*Each one reactivity in CD19-CAR-T cells: anti-Smith; anti-RNP; anti-SSA/Ro52; anti-SSA/Ro60; anti-SSB; antinucleosome; each one reactivity in RTX: rheumatoid factor.
†Haematological involvement: anaemia 2/6 (1 with evidence of haemolysis), thrombocythemia 1/6, lymphopenia 6/6 according to Easy-BILAG definition.48
ANA, antinuclear antibodies; antiSSA/Ro52, anti-Sjögren’s syndrome-related antigen A autoantibodies/Ro52; cANCA, antineutrophil cytoplasmic antibodies with diffuse granular, cytoplasmic staining pattern; CAR-T, chimeric antigen receptor T cells; dsDNA, double-stranded DNA; ENT, ear–nose–throat disease; GPA, granulomatosis polyangiitis; MSK, musculoskeletal disease; pANCA, antineutrophil cytoplasmic antibodies with peripheral staining pattern; RNP, ribonucleoprotein; RTX, rituximab; Scl-70, scleroderma 70; SLE, systemic lupus erythematosus; SSA/Ro60, anti-Sjögren’s syndrome-related antigen A/Ro60; SSB, anti-Sjogren’s syndrome-related antigen B; SSc, systemic sclerosis.